SEARCH

SEARCH BY CITATION

References

  • 1
    Wheeler CM, Franceschi S. EUROGIN 2007 roadmap—conclusion. Vaccine 2008; 26( Suppl 1): A28A31.
  • 2
    Harper DM, Paavonen J. Age for HPV vaccination. Vaccine 2008; 26( Suppl 1): A7A11.
  • 3
    Wright TC, Jr, Bosch FX. Is viral status needed before vaccination? Vaccine 2008; 26( Suppl 1): A12A15.
  • 4
    Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26( Suppl 1): A16A23.
  • 5
    Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109: S15S21.
  • 6
    Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM. EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer 2009; 125: 224655.
  • 7
    Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095101.
  • 8
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Rylander E, Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 158997.
  • 9
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 8899.
  • 10
    Bulkmans N, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke A, Bulk S, Voorhorst F, Verheijen R, van Groningen K, Boon M, Ruitinga W, van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 176472.
  • 11
    Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 67282.
  • 12
    Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 76574.
  • 13
    Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 54755.
  • 14
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492501.
  • 15
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 24957.
  • 16
    Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 161223.
  • 17
    Sasieni P, Castle PE, Cuzick J. Further analysis of the ARTISTIC trial. Lancet Oncol 2009; 10: 8412.
  • 18
    Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009; 10: 9356.
  • 19
    Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 4652.
  • 20
    Kjaer S, Hogdall E, Frederiksen K, Munk C, Van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006; 66: 106306.
  • 21
    Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
  • 22
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367: 48998.
  • 23
    Werner CL, Lo JY, Heffernan T, Griffith WF, McIntire DD, Leveno KJ. Loop electrosurgical excision procedure and risk of preterm birth. Obstet Gynecol 2010; 115: 6058.
  • 24
    Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 93745.
  • 25
    Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, Morales J, Guillen D, Sherman ME, Solomon D, Schiffman M. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009; 339: b2569.
  • 26
    Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, Ruiz F, Smith JS. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. [Epub ahead of print].
  • 27
    Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89( Suppl 2): S4S12.
  • 28
    Denny L. The prevention of cervical cancer in developing countries. BJOG 2005; 112: 120412.
  • 29
    Li N, Shi JF, Franceschi S, Zhang WH, Dai M, Liu B, Zhang YZ, Li LK, Wu RF, De VH, Plummer M, Qiao YL, et al. Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer 2009; 100: 5327.
  • 30
    Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 2007; 121: 221824.
  • 31
    Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398406.
  • 32
    Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 138594.
  • 33
    Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC, Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005; 294: 217381.
  • 34
    Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 92936.
  • 35
    IARC. IARC handbooks of cancer prevention, vol. 10: Cervix cancer screening. Lyon: IARC Press, 2005.
  • 36
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1207.
  • 37
    Kitchener H, Nelson L, Adams J, Mesher D, Sasieni P, Cubie H, Moore C, Heard I, Agarossi A, Casolati E, Denny L, Bradbeer C, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 2007; 121: 248491.
  • 38
    Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 2009; 4: 6873.
  • 39
    Kuhn L, Wang C, Tsai WY, Wright TC, Denny L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 2010; 24: 255361.
  • 40
    Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Lévy-Bruhl D; on behalf of the VENICE2 project gatekeepers group. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
  • 41
    European Medicines Agency. Cervarix, marketing authorisation. Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm 2010. Accessed 24 March 2010.
  • 42
    European Medicines Agency. Gardasil, marketing authorisation. Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm 2010. Accessed 24 March 2010.
  • 43
    Brotherton JML, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, Pitcher H, Scully M, Watson M, Webby R. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008; 32: 45761.
  • 44
    Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 101823.
  • 45
    United Nations. Official website of the United Nations Development Programme. Official website: http://www.undp.org 2010. Accessed 24 March 2010.
  • 46
    Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11: 3944.
  • 47
    Desai S, Soldan K, White J, Sheridan A, Gill ON. Human papillomavirus vaccine coverage. Lancet 2010; 376: 3289.
  • 48
    Bach PB. Gardasil: from bench, to bedside, to blunder. Lancet 2010; 375: 9634.
  • 49
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr. Accessed 10 August 2010.
  • 50
    World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009; 84: 11831.
  • 51
    World Health Organization. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009; 84: 32532.
  • 52
    World Health Organization. WHO list of vaccines for purchase by UN agencies as of October 2009. Geneva: World Health Organization, 2009. Available at: http://www.who.int/immunization_standards/vaccine_quality/pq_suppliers/en/index.html 2009. Accessed 16 March 2010.
  • 53
    Butler D. Cash crisis looms for vaccine drive. Nature 2010; 464: 338.
  • 54
    Cervical Cancer Action. GSK Announces South African Price for HPV Vaccine. Available at: http://www.cervicalcanceraction.org/news/news-detail.php?id=30 2008. Accessed 16 March 2010.
  • 55
    Eckert L, LaMontagne S, Jumaan A, Hombach J. HPV vaccine implementation in middle and low income countries. Presented at 25th International Papillomavirus Conference, Malmo, Sweden, May 2009, Poster P29.19.
  • 56
    Pan American Health Organization. Vaccination Week in the Americas. Available at: http://www.paho.org/English/dd/pin/vw2008_final.pdf. Accessed 16 March 2010.
  • 57
    Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009; 27: 3844.
  • 58
    PATH and National AIDS Research Institute (NARI). Shaping a Strategy to Introduce HPV Vaccines in India: Results from the Project. Seattle, WA: PATH; 2009. Available at: http://www.rho.org/files/PATH_FRTS_India.pdf. Accessed 16 March 2010.
  • 59
    PATH and Nutrition Research Institute (Instituto de Investigación Nutricional, or IIN). Shaping a strategy to introduce HPV vaccines in Peru: Formative research results from the Project. Seattle: PATH; 2009. Available at: http://www.rho.org/files/PATH_FRTS_Peru_eng.pdf 2009. Accessed 16 March 2010.
  • 60
    PATH and National Institute of Hygiene and Epidemiology (NIHE). Shaping a Strategy to Introduce HPV Vaccines in Vietnam: Formative Research Results from the Project. Seattle: PATH; 2009. Available at: http://www.rho.org/files/PATH_FRTS_Vietnam.pdf. Accessed 16 March 2010.
  • 61
    PATH and Child Health and Development Centre (CHDC). Shaping a Strategy to Introduce HPV Vaccines in Uganda: Formative Research Results from the Project. Seattle: PATH; 2009. Available at: http://www.rho.org/files/PATH_FRTS_Uganda. pdf 2009. Accessed 16 March 2010.
  • 62
    Jumaan AO. HPV vaccines project: evidence for impact. Presented at the XIX FIGO World Congress, Cape Town, South Africa, October 7, 2009.
  • 63
    Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, Gandhi S. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009; 27: 62039.
  • 64
    Jacob M, Mawar N, Menezes L, Kaipilyawar S, Gandhi S, Khan I, Manoj P, Bingham A, LaMontagne DS, Bagul R, Katendra T, Karandikar N, et al. Assessing the environment for introduction of human papillomavirus vaccine in India. Open Vaccine J 2010; 3: 96107.
  • 65
    Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet 2010; 376: 5723.
  • 66
    Le Tallec D, Doucet D, Elouahabi A, Harvengt P, Deschuyteneer M, Deschamps M. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccin 2009; 5: 46774.
  • 67
    Shank-Retzlaff ML, Zhao Q, Anderson C, Hamm M, High K, Nguyen M, Wang F, Wang N, Wang B, Wang Y, Washabaugh M, Sitrin R, et al. Evaluation of the thermal stability of Gardasil. Hum Vaccin 2006; 2: 14754.
  • 68
    Esposito S, Birlutiu V, Jarcuska P, Perino A, Man S, Vladareanu R, Meric D, Dobbeleare K, Thomas F, Descamps D. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule. Presented at EUROGIN, Monte Carlo, Monaco, February 17–20, 2010, Poster VC-1.
  • 69
    Dobson S, Dawar M, Scheifele D, Kollmann T, McNeil S, Halperin S, Langley J, Dionne M, Picard ME, Sauvageau C, Krajden M, Marra F, et al. Are 2 doses of vaccine adequate in girls? Presented at 25th International Papillomavirus Conference, Malmo, Sweden, May 2009.
  • 70
    Romanowski B. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results. Abstract presented at the 26th International Papillomavirus Congress (IPC), Montreal, 2010.
  • 71
    Gilca V, Sauvageau C, Boulianne N, De Wals P, De Serres G, Dionne D. Using evidence for an extended HPV immunization schedule in pre-adolescent girls. Poster presented at the 26th International Papillomavirus Conference and Clinical and Public Health Workshops, Montréal, July 3–8, 2010.
  • 72
    Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller J. Proof-of-principle: efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica. Presented at the 26th International Papillomavirus Conference and Clinical and Public Health Workshops, Montréal, July 3–8, 2010.
  • 73
    Sankaranarayanan R. International Agency for Research on Cancer. Randomized trial of 2 versus 3 doses of HPV vaccine in India. Available at: http://screening.iarc.fr/hpvvaccine.php. Accessed 1 February 2011.
  • 74
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26: 408093.
  • 75
    International AIDS Vaccine Initiative/PATH. HPV Vaccine Adoption in Developing Countries: Cost and Financing Issues. December 2007. Available at: http://www.rho.org/files/IAVI_PATH_HPV_financing.pdf 2007. Accessed 16 March 2010.
  • 76
    Pan American Health Organization. Vaccine revolving fund may expand to Africa, Eastern Mediterranean regions. Available at: http://new.paho.org/hq/index.php?option=com_content&task= view&id=1553&Itemid=259 2008. Accessed 16 March 2010.
  • 77
    Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT. Introduction of human papillomavirus vaccines into developing countries—international strategies for funding and procurement. Vaccine 2008; 26( Suppl 10): K87K92.
  • 78
    Cervical Cancer Action. The global call to stop cervical cancer. Available at: http://www.cervicalcanceraction.org/ call/thecall.php 2010. Accessed 16 March 2010.
  • 79
    Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009; 101: 78292.